1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Samsung Bioepis Moves Forward With Soliris Rival

Completes Phase III Trial For SB12 Proposed Eculizumab Biosimilar

 
• By Dave Wallace

Samsung Bioepis has confirmed completion of its Phase III trial for a proposed biosimilar to Soliris, putting it ahead of rival developer Amgen which has negotiated a date-certain US launch.

Eculizumab mab word pink
Samsung Bioepis has completed its Phase III trial for eculizumab • Source: Alamy

Samsung Bioepis says it has moved ahead with its proposed biosimilar version of Alexion’s Soliris (eculizmab) after the joint venture between Samsung Biologics and Biogen completed a Phase III clinical trial for its SB12 candidate.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products